SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that Fred R. Hirsch, M.D., Ph.D. has joined its Clinical Advisory Board.  Dr. Hirsch is Professor of Medicine and Pathology at the University of Colorado Cancer Center.

"I am excited to join Biocept as a clinical advisor as the Company develops and expands its liquid biopsy offering," said Dr. Hirsch.  "The ability to rapidly and non-invasively determine actionable biomarkers present in a patient's tumor can optimize personalized treatment.  Biocept's use of highly sensitive assays for both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) to accomplish this is a novel approach that holds promise for improving cancer profiling and treatment."

"We welcome Dr. Hirsch to our Clinical Advisory Board and look forward to benefitting from his significant expertise in lung cancer," said Biocept's President and Chief Executive Officer Michael Nall.  "Dr. Hirsch is a prominent figure in the clinical and academic communities focused on lung cancer, and has received numerous awards and authored hundreds of peer-reviewed papers.  He is involved in studies of lung cancer diagnosis, staging, prevention, early detection and treatment that have favorably impacted the care of lung cancer patients, and his research has helped to identify and validate predictive markers for personalized lung cancer therapies.

"We are extremely proud of our ability to attract the leading advisors assembled on our Clinical Advisory Board in order to support our objective of improving the outcomes of patients with cancer," added Nall.  "This group is playing an important advisory role in helping us understand how our tests are being used in a clinical setting and on other aspects of our business, as liquid biopsy moves toward standard of care."

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer.  Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to identify specific clinical conditions or improve the outcomes of cancer patients, the utility and effectiveness of our intellectual property protections, the financial impact of new contracts including the retention of services of certain physicians or other individuals, and our ability to increase the number of products or services provided or the value of the Company, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at www.sec.gov

© 2024 Canjex Publishing Ltd. All rights reserved.